6533b7dafe1ef96bd126ed06
RESEARCH PRODUCT
Pharmacokinetics of Droloxifene and Its Metabolites in Breast Cancer Patients
K. PollowH. J. Grillsubject
AdultOncologyDrugCancer Researchmedicine.medical_specialtymedia_common.quotation_subjectAdministration OralBiological AvailabilityAntineoplastic AgentsBreast NeoplasmsBioequivalenceBreast cancerPharmacokineticsInternal medicinemedicineHumansChromatography High Pressure LiquidAgedmedia_commonAged 80 and overbusiness.industryEstrogen AntagonistsCancerMiddle AgedAntiestrogenmedicine.diseaseTamoxifenOncologyTolerabilityDroloxifeneDrug EvaluationFemalebusinessHalf-Lifedescription
Pharmacokinetics and metabolism of droloxifene, a new antiestrogenic drug, have been investigated by single- and multiple-dose studies in postmenopausal patients with advanced breast cancer. Short terminal elimination half-life, low accumulation, and improved drug tolerability are the most striking features of this safe and effective new antiestrogen. Bioequivalence of film-coated tablet, tablet, and standard solution of droloxifene has been shown. The concentrations of droloxifene and its metabolites have been determined by a highly selective HPLC method.
year | journal | country | edition | language |
---|---|---|---|---|
1991-01-01 | American Journal of Clinical Oncology |